Investors

2022

TruSpine Technologies plc (AQSE: TSP), the medical device company focused on the spinal (vertebral) stabilisation market, announces an update to the announcement released by the Company on 24 December 2020 in which it notified that the subscription funds of £250,000 ("Funds") from Evrensel Capital Partners Limited ("ECP") would be received by 5 January 2021 for the subscription for 694,444 new ordinary shares in the Company at a price of 36 pence per share.

The Company further advises that the Funds have not been received by the Company, however the Company and ECP have reached a further agreement to extend the deadline for the subscription date to 28 February 2021.

The Company confirms that it is not reliant on these additional funds for its current working capital requirements.

Ian Roberts, CEO, commented: "Whilst the delay in the subscription is frustrating, we are in constant communication with Evrensel Capital Partners Limited. Both the Company and ECP remain committed to a long-term relationship and feel confident this delay is only temporary."

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").

The Directors of the Company take responsibility for this announcement.

Enquiries:

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as ''believe'', ''could'', "should" ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect", ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.

2021

TruSpine Technologies plc (AQSE: TSP), the medical device company focused on the spinal (vertebral) stabilisation market, announces an update to the announcement released by the Company on 24 December 2020 in which it notified that the subscription funds of £250,000 ("Funds") from Evrensel Capital Partners Limited ("ECP") would be received by 5 January 2021 for the subscription for 694,444 new ordinary shares in the Company at a price of 36 pence per share.

The Company further advises that the Funds have not been received by the Company, however the Company and ECP have reached a further agreement to extend the deadline for the subscription date to 28 February 2021.

The Company confirms that it is not reliant on these additional funds for its current working capital requirements.

Ian Roberts, CEO, commented: "Whilst the delay in the subscription is frustrating, we are in constant communication with Evrensel Capital Partners Limited. Both the Company and ECP remain committed to a long-term relationship and feel confident this delay is only temporary."

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").

The Directors of the Company take responsibility for this announcement.

Enquiries:

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as ''believe'', ''could'', "should" ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect", ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.

2020

TruSpine Technologies plc (AQSE: TSP), the medical device company focused on the spinal (vertebral) stabilisation market, announces an update to the announcement released by the Company on 24 December 2020 in which it notified that the subscription funds of £250,000 ("Funds") from Evrensel Capital Partners Limited ("ECP") would be received by 5 January 2021 for the subscription for 694,444 new ordinary shares in the Company at a price of 36 pence per share.

The Company further advises that the Funds have not been received by the Company, however the Company and ECP have reached a further agreement to extend the deadline for the subscription date to 28 February 2021.

The Company confirms that it is not reliant on these additional funds for its current working capital requirements.

Ian Roberts, CEO, commented: "Whilst the delay in the subscription is frustrating, we are in constant communication with Evrensel Capital Partners Limited. Both the Company and ECP remain committed to a long-term relationship and feel confident this delay is only temporary."

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").

The Directors of the Company take responsibility for this announcement.

Enquiries:

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as ''believe'', ''could'', "should" ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect", ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.